Ligand ID: HLZ Drugbank ID: DB01275(Hydralazine) Indication:For the treatment of essential hypertension, alone or as an adjunct. Also for the management of severe hypertension when the drug cannot be given orally or when blood pressure must be lowered immediately, congestive heart failure (in combination with cardiac glycosides and diuretics and/or with isosorbide dinitrate), and hypertension secondary to pre-eclampsia/eclampsia. |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 1xak | ORF7A ACCESSORYPROTEIN (SARSr-CoV) | 4 / 6 | PHE A 39TYR A 25THR A 59PHE A 48 | 1.62A | 18.60 | None | ||
![]() | 3LTW_A_HLZA302_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 2g9t | ORF1A POLYPROTEIN (SARSr-CoV) | 4 / 6 | LEU B 14PRO B 8ARG B 78HIS B 80 | 1.69A | 18.64 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 2ghw | SPIKE GLYCOPROTEIN (SARSr-CoV) | 4 / 6 | PHE A 325TYR A 352VAL A 498PHE A 501 | 1.45A | 20.07 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 2ghw | ANTI-SCFV ANTIBODY,80R (Homosapiens) | 4 / 6 | PHE B 68TYR B 94VAL B 12THR B 114 | 1.80A | 23.45 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 2gri | NSP3 (SARSr) | 4 / 6 | PHE A 107CYH A 105VAL A 62PHE A 88 | 1.28A | 16.61 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 2xyq | PUTATIVE 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 4 / 6 | PHE A 70VAL A 290THR A 120PHE A 156 | 1.68A | 21.04 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 2xyv | PUTATIVE 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 4 / 6 | PHE A 70VAL A 290THR A 120PHE A 156 | 1.66A | 21.04 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 3bgf | SPIKE PROTEIN S1 (SARSr-CoV) | 4 / 6 | PHE A 416TYR A 367VAL A 496THR A 363 | 1.64A | 19.54 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 3r24 | 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 4 / 6 | PHE A 70VAL A 290THR A 120PHE A 156 | 1.70A | 22.28 | None | ||
![]() | 3LTW_A_HLZA302_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 5c8t | NSP10 (SARSr-CoV) | 4 / 6 | LEU A 14GLU A 6PRO A 8ARG A 78 | 1.38A | 17.86 | None | ||
![]() | 3LTW_A_HLZA302_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 5nfy | POLYPROTEIN 1AB (SARS-COVFrankfurt1) | 4 / 6 | LEU M 14GLU M 6PRO M 8HIS M 80 | 1.50A | 17.38 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 5x4r | S PROTEIN (MERS-CoV) | 4 / 6 | PHE A 281VAL A 263THR A 257PHE A 254 | 1.68A | 21.41 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 5x4s | SPIKE GLYCOPROTEIN (SARSr-CoV) | 4 / 6 | PHE A 231TYR A 252VAL A 66PHE A 69 | 1.79A | 21.73 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 5x5b | SPIKE GLYCOPROTEIN (SARS-COVBJ01) | 4 / 6 | PHE B 741TYR B 738THR A 980PHE A 952 | 1.45A | 12.67 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 5x5c | S PROTEIN (MERS-CoV) | 4 / 6 | PHE B 281VAL B 263THR B 257PHE B 254 | 1.67A | 12.88 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6acg | SPIKE GLYCOPROTEIN (SARSr-CoV) | 4 / 6 | PHE A 741TYR A 738THR B 980PHE B 952 | 1.36A | 12.79 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6acg | ACE2 (Homosapiens) | 4 / 6 | PHE D 512TYR D 515VAL D 226THR D 517 | 1.79A | 17.74 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6crv | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 4 / 6 | PHE B 741TYR B 738THR A 980PHE A 952 | 1.70A | 12.97 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6crz | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 4 / 6 | PHE B 22VAL B 97THR B 71PHE B 76 | 1.59A | 12.97 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6jyt | HELICASE (SARSr-CoV) | 4 / 6 | CYH A 19VAL A 34THR A 37PHE A 106 | 1.59A | 17.05 | ZN A 703 (-2.2A)NoneNoneNone | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6lzg | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 6 | PHE B 429TYR B 380VAL B 510THR B 376 | 1.63A | 18.84 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 6 | PHE A 859TYR A 887VAL A 880PHE A 419 | 1.52A | 15.82 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 6 | TYR A 483CYH A 482THR A 586PHE A 480 | 1.73A | 15.82 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 6 | TYR A 420CYH A 842VAL A 880PHE A 429 | 1.78A | 15.82 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6nb8 | S230 ANTIGEN-BINDING(FAB) FRAGMENT,HEAVY CHAINS230 ANTIGEN-BINDING(FAB) FRAGMENT,LIGHT CHAIN (Homosapiens) | 4 / 6 | PHE L 41TYR L 92VAL H 37PHE L 103 | 1.54A | 21.02 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6nur | NSP12 (SARSr-CoV) | 4 / 6 | TYR A 483CYH A 482THR A 586PHE A 480 | 1.68A | 15.34 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 6 | PHE B 759TYR B 756THR A 998PHE A 970 | 1.57A | 11.91 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6vw1 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 6 | PHE E 429TYR E 380VAL E 510THR E 376 | 1.69A | 19.86 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 6 | PHE B 759TYR B 756THR A 998PHE A 970 | 1.79A | 12.20 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6w41 | SPIKE PROTEIN S1 (SARS-CoV-2) | 4 / 6 | PHE C 429TYR C 380VAL C 510THR C 376 | 1.75A | 20.74 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | PHE A6868TYR A6950THR A6918PHE A6954 | 1.63A | 21.25 | NoneFMT A7109 ( 4.9A)FMT A7109 ( 4.5A)None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | PHE C6868TYR C6950THR C6918PHE C6954 | 1.62A | 21.25 | NoneNoneFMT C7113 ( 4.8A)None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 6 | PHE C 173VAL C 165THR C 115PHE C 304 | 1.55A | 20.55 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 6 | PHE B 173VAL B 165THR B 115PHE B 304 | 1.54A | 20.55 | NoneNone CL B 502 ( 4.9A)None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 6 | PHE A 173VAL A 165THR A 115PHE A 304 | 1.46A | 20.55 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | PHE C6868TYR C6950THR C6918PHE C6954 | 1.60A | 21.66 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | PHE A6868VAL A7086THR A6918PHE A6954 | 1.71A | 21.66 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 6 | PHE A6868TYR A6950THR A6918PHE A6954 | 1.68A | 21.66 | NoneNoneFMT A7108 ( 4.8A)None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 6 | PHE C6868TYR C6950THR C6918PHE C6954 | 1.62A | 21.66 | NoneNoneFMT C7108 ( 4.9A)None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 6 | PHE A6868VAL A7086THR A6918PHE A6954 | 1.75A | 21.66 | NoneNoneFMT A7108 ( 4.8A)None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | PHE A6868VAL A7086THR A6918PHE A6954 | 1.70A | 21.66 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6wrh | NSP3 (SARS-CoV-2) | 4 / 6 | PHE A 173VAL A 165THR A 115PHE A 304 | 1.34A | 20.97 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 6 | PHE E 429TYR E 380VAL E 510THR E 376 | 1.71A | 19.31 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 6 | PHE A 429TYR A 380VAL A 510THR A 376 | 1.73A | 19.31 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6ym0 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 6 | PHE E 429TYR E 380VAL E 510THR E 376 | 1.72A | 19.31 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 6 | PHE A 429TYR A 380VAL A 510THR A 376 | 1.71A | 20.08 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 6 | PHE E 429TYR E 380VAL E 510THR E 376 | 1.71A | 20.08 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 7btf | NSP12 (SARS-CoV-2) | 4 / 6 | TYR A 483CYH A 482THR A 586PHE A 480 | 1.74A | 15.82 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 7btf | NSP12 (SARS-CoV-2) | 4 / 6 | PHE A 859TYR A 887VAL A 880PHE A 419 | 1.56A | 15.82 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | TYR A 420CYH A 842VAL A 880PHE A 429 | 1.76A | 15.00 | None | ||
![]() | 3LTW_A_HLZA300_1 (ARYLAMINEN-ACETYLTRANSFERASENAT) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | TYR A 483CYH A 482THR A 586PHE A 480 | 1.70A | 15.00 | None |